Jefferies upgrades Dr. Reddy’s stock rating on margin outlook

Jefferies upgraded Dr. Reddy’s Laboratories (RDY) from Underperform to Hold, raising its price target to INR1,320.00. The firm cited a 15% Ebitda beat in Q3, strong margins, and improved earnings estimates. Dr. Reddy’s reported $905M in revenue, slightly above forecasts, with improved margins. The company expects to resume Semaglutide supplies and U.S. approval for bAbatacept in late 2026.

Original reporting
Published Oct 25, 2026, 3:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 25, 2026, 3:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$RDY
Bullish
high confidence
Mentioned
$RDY
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$RDYBullishMed
01

Why it matters

The analyst's revised earnings estimates and price target provide a new data point for traders.

02

Market read

Analyst upgrade with higher target may trigger buying interest in RDY.

03

What to watch

Potential regulatory risks for upcoming drug approvals could temper upside.

Relevance 6/10Novelty 6/10Timing: today

Background

Jefferies' research note highlights Dr. Reddy's recent earnings beat and margin recovery.

Company-level read

Ticker impact

$RDYBullishHigh confidence
Context

Jefferies upgraded Dr. Reddy's Laboratories (RDY) to Hold and raised its price target to INR1,320, citing a 15% EBITDA beat and higher margin outlook.

Expected impact

likely upward pressure as the market prices in the margin-driven earnings outlook.

Evidence & confidence

Analyst upgrade with a new target is a fresh catalyst that can move the stock in the short term.

Market effects

Improved margin outlook may lift other Indian pharma peers.

Positive for the Indian healthcare sector.

Limited to investors tracking emerging market pharma.

Counterpoint

The upgrade to Hold may be modest; investors could wait for further guidance before buying.

Key entities

  • Jefferies

    Provided the upgrade and target revision.

  • Dr. Reddy's Laboratories

    Subject of the upgrade and earnings beat.

Related articles

$RDYHigh

Dr.Reddy's Wins Brazil Approval For Generic Ozempic Alternative

Dr. Reddy's Laboratories (RDY) received approval from Brazil's ANVISA for its generic semaglutide injection, a diabetes treatment similar to Novo Nordisk's Ozempic. The product will be marketed in Brazil, a key market with 16.6 million diabetes patients and a $244.6 million semaglutide market. RDY plans to launch the product via a partnership with Ache. RDY stock closed at $14.77, up 3.29%, and is down 0.10% in pre-market trading.

$RDYMed

Dr Reddy's Laboratories Ltd (RDY) (Q2 2027) Earnings Call Highlights: Margin Recovery

Dr. Reddy's Laboratories reported a 1.5% year-over-year revenue decline, driven by lower lenalidomide sales and declines in North America, Europe, and PSAI businesses. The company expects margins to improve with new products and business mix, targeting a 55% gross margin. Semaglutide relaunch is planned for November 2026, and abatacept biosimilar approval is expected by December 2026.

$RDYHigh

DR REDDYS LABORATORIES LTD (RDY): Financial results for H1 2027

DR REDDYS LABORATORIES LTD (RDY) furnished an SEC Form 6-K — earnings release. Exhibit 99.2 CONTACT DR. REDDY’S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. Investor relationS Media relationS AISHWARYA SITHARAM SANTOSH VYAS aishwaryasitharam@drreddys.com santoshvyas@drreddys.com Dr. Reddy’s Q2 & H1FY27 Financia